{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T20:47:27Z","timestamp":1787950047137,"version":"build-2784847793"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T00:00:00Z","timestamp":1697068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T00:00:00Z","timestamp":1697068800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100012247","name":"Program of Shanghai Academic Research Leader","doi-asserted-by":"publisher","award":["20XD1403300"],"award-info":[{"award-number":["20XD1403300"]}],"id":[{"id":"10.13039\/501100012247","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073429"],"award-info":[{"award-number":["82073429"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273510"],"award-info":[{"award-number":["82273510"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203913"],"award-info":[{"award-number":["82203913"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Innovation Program of Shanghai Municipal Education Commission","award":["2019-01-07-00-07-E00046"],"award-info":[{"award-number":["2019-01-07-00-07-E00046"]}]},{"name":"Clinical Research Plan of SHDC","award":["SHDC2020CR1014B"],"award-info":[{"award-number":["SHDC2020CR1014B"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s12325-023-02672-1","type":"journal-article","created":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T06:01:47Z","timestamp":1697090507000},"page":"5464-5474","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Safety and Efficacy of Ixekizumab in Chinese Adults with Moderate-to-Severe Plaque Psoriasis: A Prospective, Multicenter, Observational Study"],"prefix":"10.1007","volume":"40","author":[{"given":"Li","family":"Ying","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Suyun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Yanhua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Yunsheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lv","family":"Chengzhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Bingjiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhang","family":"Furen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Wendi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Jinnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dou","family":"Guanshen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1273-7881","authenticated-orcid":false,"given":"Yuling","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,12]]},"reference":[{"issue":"1","key":"2672_CR1","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/JD9.0000000000000074","volume":"3","author":"Committee of Psoriasis DB, Chinese Medical Association","year":"2020","unstructured":"Committee of Psoriasis DB, Chinese Medical Association. Guidelines for the Diagnosis and Treatment of Psoriasis in China: 2019 Concise Edition#. Int J Dermatol Venereol. 2020;3(1):14\u201326.","journal-title":"Int J Dermatol Venereol"},{"issue":"5","key":"2672_CR2","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1684\/ejd.2012.1802","volume":"22","author":"X Ding","year":"2012","unstructured":"Ding X, Wang T, Shen Y, Wang X, Zhou C, Tian S, et al. Prevalence of psoriasis in China: a population-based study in six cities. Eur J Dermatol. 2012;22(5):663\u20137.","journal-title":"Eur J Dermatol"},{"issue":"5","key":"2672_CR3","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1056\/NEJMra0804595","volume":"361","author":"FO Nestle","year":"2009","unstructured":"Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496\u2013509.","journal-title":"N Engl J Med"},{"issue":"28","key":"2672_CR4","doi-asserted-by":"publisher","first-page":"46381","DOI":"10.18632\/oncotarget.18453","volume":"8","author":"K Chen","year":"2017","unstructured":"Chen K, Wang G, Jin H, Xu J, Zhu X, Zheng M, et al. Clinic characteristics of psoriasis in China: a nationwide survey in over 12000 patients. Oncotarget. 2017;8(28):46381\u20139.","journal-title":"Oncotarget"},{"issue":"3","key":"2672_CR5","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1111\/jdv.12572","volume":"29","author":"T Hawro","year":"2015","unstructured":"Hawro T, Zalewska A, Hawro M, Kaszuba A, Krolikowska M, Maurer M. Impact of psoriasis severity on family income and quality of life. J Eur Acad Dermatol Venereol. 2015;29(3):438\u201343.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"2672_CR6","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1186\/s12955-021-01902-w","volume":"19","author":"H Zhong","year":"2021","unstructured":"Zhong H, Yang H, Mao Z, Chai X, Li S. Impact of moderate-to-severe psoriasis on quality of life in China: a qualitative study. Health Qual Life Outcomes. 2021;19(1):271.","journal-title":"Health Qual Life Outcomes"},{"key":"2672_CR7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/JIR.S100940","volume":"9","author":"L Liu","year":"2016","unstructured":"Liu L, Lu J, Allan BW, Tang Y, Tetreault J, Chow CK, et al. Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A. J Inflamm Res. 2016;9:39\u201350.","journal-title":"J Inflamm Res"},{"issue":"1","key":"2672_CR8","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jaci.2012.04.024","volume":"130","author":"JG Krueger","year":"2012","unstructured":"Krueger JG, Fretzin S, Suarez-Farinas M, Haslett PA, Phipps KM, Cameron GS, et al. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol. 2012;130(1):145-54e9.","journal-title":"J Allergy Clin Immunol"},{"issue":"9993","key":"2672_CR9","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","volume":"386","author":"CE Griffiths","year":"2015","unstructured":"Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541\u201351.","journal-title":"Lancet"},{"issue":"4","key":"2672_CR10","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1056\/NEJMoa1512711","volume":"375","author":"KB Gordon","year":"2016","unstructured":"Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(4):345\u201356.","journal-title":"N Engl J Med"},{"key":"2672_CR11","doi-asserted-by":"publisher","DOI":"10.1097\/JD9.0000000000000244","author":"X Li","year":"2022","unstructured":"Li X, Zheng J, Pan W, Zheng M, Lu Y, Li F, et al. Efficacy and safety of ixekizumab in Chinese patients with moderate-to-severe plaque psoriasis: 60-week results from a phase 3 study. Int J Dermatol Venereol. 2022. https:\/\/doi.org\/10.1097\/JD9.0000000000000244.","journal-title":"Int J Dermatol Venereol"},{"issue":"2","key":"2672_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14808","volume":"34","author":"B Lockshin","year":"2021","unstructured":"Lockshin B, Cronin A, Harrison RW, McLean RR, Anatale-Tardiff L, Burge R, et al. Drug survival of ixekizumab, TNF inhibitors, and other IL-17 inhibitors in real-world patients with psoriasis: the Corrona Psoriasis Registry. Dermatol Ther. 2021;34(2): e14808.","journal-title":"Dermatol Ther"},{"key":"2672_CR13","unstructured":"Grace E, Zhu B, Malley W, O'Brien J, Mangner R, Agada N, et al., editors. Safety events occurring among patients exposed to ixekizumab in the Corrona Psoriasis Registry. In: 6th Congress of the Skin Inflammation and Psoriasis International Network; Paris, France; 25\u201327 April 2019."},{"issue":"4","key":"2672_CR14","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.jaad.2019.11.015","volume":"82","author":"A Blauvelt","year":"2020","unstructured":"Blauvelt A, Shi N, Burge R, Malatestinic WN, Lin CY, Lew CR, et al. Comparison of real-world treatment patterns among patients with psoriasis prescribed ixekizumab or secukinumab. J Am Acad Dermatol. 2020;82(4):927\u201335.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"2672_CR15","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/j.0022-202X.2005.23621.x","volume":"125","author":"Y Hongbo","year":"2005","unstructured":"Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY. Translating the science of quality of life into practice: what do dermatology life quality index scores mean? J Invest Dermatol. 2005;125(4):659\u201364.","journal-title":"J Invest Dermatol"},{"issue":"3","key":"2672_CR16","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s13555-020-00367-x","volume":"10","author":"C Leonardi","year":"2020","unstructured":"Leonardi C, Reich K, Foley P, Torii H, Gerdes S, Guenther L, et al. Efficacy and safety of ixekizumab through 5 years in moderate-to-severe psoriasis: long-term results from the UNCOVER-1 and UNCOVER-2 PHASE-3 RANDOMIZED CONTROLLED TRIALS. Dermatol Ther (Heidelb). 2020;10(3):431\u201347.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"5","key":"2672_CR17","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1684\/ejd.2020.3878","volume":"30","author":"H Huang","year":"2020","unstructured":"Huang H, Cai ML, Hong XJ, Zheng LJ, Hu ZL, Yuan T, et al. Real-world data on the use of secukinumab as treatment for moderate-to-severe psoriasis in Chinese patients. Eur J Dermatol. 2020;30(5):554\u201360.","journal-title":"Eur J Dermatol"},{"key":"2672_CR18","doi-asserted-by":"publisher","first-page":"2546161","DOI":"10.1155\/2019\/2546161","volume":"2019","author":"F Bai","year":"2019","unstructured":"Bai F, Li GG, Liu Q, Niu X, Li R, Ma H. Short-Term efficacy and safety of IL-17, IL-12\/23, and IL-23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab for the treatment of moderate to severe plaque psoriasis: a systematic review and network meta-analysis of randomized controlled trials. J Immunol Res. 2019;2019:2546161.","journal-title":"J Immunol Res"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02672-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02672-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02672-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T11:11:04Z","timestamp":1698405064000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02672-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,12]]},"references-count":18,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["2672"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02672-1","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,12]]},"assertion":[{"value":"13 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Shi Wendi, Li Jinnan, Dong Yu and Dou Guanshen are employees from Eli Lilly China. Li Ying, Ji Suyun, Liang Yanhua, Liang Yunsheng, Deng Li, Dang Lin, Lv Chengzhi, Lin Bingjiang, Zhang Furen, and Yuling Shi have no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was conducted in compliance with Good Clinical Practice and the Declaration of Helsinki. The study protocol and its amendments were approved by Independent Ethics Committees at each study center (Table S1). All patients provided written, informed consent prior to participating in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}